MIRIMMUNE
MirImmune is a biopharmaceutical company focused on the development of new and improved immunotherapies for cancer. Aiming to achieve long-term survival of cancer patients, MirImmune combine two leading approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies.
MIRIMMUNE
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.mirimmunebio.com
Status:
Active
Contact:
508-767-3861
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Google Analytics Content Delivery Network Apache Google Analytics Classic Unified Layer CentOS Apache 2.2 BlueHost
Similar Organizations
AGI Biopharmaceuticals
AGI Biopharmaceuticals offers a patented melanoma vaccine with future multi-cancer applications.
ImmunSYS
ImmunSYS is a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products.
Rare Partners
Rare Partners s.r.l. is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases
Selonterra
Selonterra is a biopharmaceutical company that works on Alzheimer's and Parkinson's disease therapies and diagnostics.
Current Employees Featured
Founder
Official Site Inspections
http://www.mirimmunebio.com
- Host name: parking.bluehost.com
- IP address: 74.220.199.6
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "MirImmune"
MirImmune - Crunchbase Company Profile & Funding
Organization. MirImmune . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number 508 …See details»
MirImmune - Headquarter Location, Corporate Office Address and …
About. MirImmune is Drug Discovery in United States that focus on cell-based immunotherapies business. Founded in 2014. They cover business area such as developer, immunotherapy …See details»
MirImmune 2025 Company Profile: Valuation, Investors
MirImmune General Information Description. Developer of immunotherapy treatments for cancer. The company is focused on development of therapies for long-term survival of cancer patients, …See details»
MirImmune - Ownership and Business Overview - Mergr
United States, www.mirimmunebio.com. Profile Investors (1) Analytics MirImmune, Inc. is a biopharmaceutical company focused on the development of new generation immunotherapies …See details»
MirImmune - Products, Competitors, Financials, Employees, …
MirImmune is a biopharmaceutical company focusing on the development of immunotherapies for cancer by combining two approaches to cancer treatment: immune checkpoint inhibition and …See details»
MirImmune Inc - Company Profile and News - Bloomberg Markets
Company profile page for MirImmune Inc including stock price, company news, executives, board members, and contact informationSee details»
Nextsource | Company Profile | MirImmune
Explore the company profile of MirImmune (mirimmunebio.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and ...
MARLBOROUGH, Mass., Jan. 9, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that …See details»
Mirimmune Bio - Company Profile - Tracxn
Mirimmune Bio - Adoptive T cell therapy for cancer. Founded by Alexey Eliseev in the year 2015. Mirimmune Bio has 3003 competitors.See details»
MirImmune - Crunchbase
MirImmune is a biopharmaceutical company focused on the development of new and improved immunotherapies for cancer.See details»
Mirimmune Bio - Founders and Board of Directors - Tracxn
Feb 23, 2025 Mirimmune Bio's founder is Alexey Eliseev. Corporates and Startups. Corp Dev and M&A Teams Corporate Innovation Startup Founders Sales TeamSee details»
MirImmune, Inc. (米尔伊姆恩股份有限公司) - 药物管线_专利_临床 …
了解MirImmune, Inc. (米尔伊姆恩股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的。See details»
MirImmune’s Competitors, Revenue, Number of Employees
MirImmune’s Profile, Revenue and Employees. MirImmune researches and develops immunotherapies for the treatment of cancer. MirImmune’s primary competitors include …See details»
MirImmune - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. MirImmune . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 10. About. MirImmune is actively …See details»
MirImmune - CB Insights
See MirImmune funding rounds, investors, investments, exits and more. Evaluate their financials based on MirImmune's post-money valuation and revenue.See details»
Rxi lays foundation for Mirimmune buy + | Bioworld | BioWorld
Rxi Pharmaceuticals Corp. negotiated an exclusive option to acquire privately held cancer immunotherapy developer Mirimmune Inc. The all-stock deal will give Mirimmune shareholders …See details»
Mirimmunebio Web Analysis - Mirimmunebio.com
Mirimmunebio.com is 1 decade 10 months old. It is a domain having com extension. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats …See details»
Overview — MirBio
Mir Bio’s immunogens consist of a non-infectious bacterial protein fused to a full-length antigen or peptide of interest. Our researchers and industry partners have demonstrated the ability our …See details»
Home Page - NImmune
Apr 10, 2025 The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will …See details»
Company Details :: In Vivo
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183See details»